| Authors: |
Miyazaki I; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp., Odintsov I; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ishida K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Lui AJW; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Kato M; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Suzuki T; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Zhang T; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wakayama K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Kurth RI; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cheng R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fujita H; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Delasos L; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Vojnic M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA., Khodos I; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yamada Y; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Ishizawa K; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan., Mattar MS; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Funabashi K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Chang Q; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ohkubo S; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Yano W; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Terada R; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Giuliano C; Helsinn Healthcare SA, Lugano, Switzerland., Lu YC; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bonifacio A; Helsinn Healthcare SA, Lugano, Switzerland., Kunte S; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Dana Cancer Center, Toledo, OH, USA., Davare MA; Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA., Cheng EH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Stanchina E; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lovati E; Helsinn Healthcare SA, Lugano, Switzerland., Iwasawa Y; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Somwar R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org. |
